Latham & Watkins Represents Lincoln International in NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Merger Agreement

NewAmsterdam Pharma Holding B.V. (Company), a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, and Frazier Lifesciences Acquisition Corporation (FLAC), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, a newly formed holding company, NewAmsterdam Pharma Company N.V. (NewAmsterdam) will be led by Michael Davidson, M.D., Chief Executive Officer of the Company. NewAmsterdam’s ordinary shares are expected to be listed on Nasdaq under the ticker symbol “NAMS.”

Latham & Watkins LLP advised Lincoln International in the matter with a M&A deal team led by Los Angeles partner Steven Stokdyk and Century City/New York counsel Adam Rachlis, with associate Eric Czubiak.